Citations

Citations to this article as recorded by  

• Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease
  Ke Yin, Yuyun Song, Ran Fei, Xu Cong, Baiyi Liu, Zilong Wang, Xin Ai, Minjun Liao, Yayun Ren, Kutbuddin Akbary, Wei Wang, Qiang Yang, Xiao Teng, Nan Wu, Huiying Rao, Xiaoxiao Wang, Feng Liu
  Diagnostics.2026; 16(2): 234.     CrossRef
• The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
  Denisia Adelina Tornea, Christian Goldis, Alexandru Isaic, Alexandru Catalin Motofelea, Alexandra Christa Sima, Tudor Ciocarlie, Andreea Crintea, Razvan Gheorghe Diaconescu, Nadica Motofelea, Adrian Goldis
  Pharmaceutics.2026; 18(1): 86.     CrossRef
• Metabolic Syndrome in Focus: Emerging Causes, New Diagnostic Approaches and Criteria, and Long-Term Health Consequences
  Michalina Loson-Kawalec, Piotr Sawina, Anna Kowalczyk, Estera Pazek, Dorota Szydłowska, Julia Pawlowska, Dawid Boczkowski, Aleksandra Wielochowska, Dawid Szymanski, Mateusz Podkanowicz, Maciej Majchrzak, Tomasz Dolata, Weronika Majchrowicz, Patrycja Dadyn
  Cureus.2026;[Epub]     CrossRef
• Activating the Osteoblastic USP26 Pathway Alleviates Multi‐Organ Fibrosis by Decreasing Insulin Resistance
  Jiyuan Tang, Wenkai Ye, Liang He, Zhou Dan, Leilei Chang, Zijie You, Yuanyue Jiang, Guoqing Tang, Lianfu Deng, Changwei Li
  Advanced Science.2026;[Epub]     CrossRef
• Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications
  Mohamad Jamalinia, Ralf Weiskirchen, Amedeo Lonardo
  Medical Sciences.2026; 14(1): 44.     CrossRef
• The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics
  Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao
  Microorganisms.2026; 14(2): 471.     CrossRef
• Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma
  Daniel Neureiter, Tobias Kiesslich, Matthias Ocker
  Medical Sciences.2026; 14(1): 110.     CrossRef
• Metabolic liver imaging: What you need to know
  Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T. Pierce, Jingwei Wei, Angelo Vanzulli
  Digestive and Liver Disease.2026; 58(4): 433.     CrossRef
• The many pathways driving liver inflammation in MASH
  Herbert Tilg, Timon E. Adolph, Stefano Romeo, Rohit Loomba
  Cell Metabolism.2026; 38(6): 1054.     CrossRef
• Association of metabolic syndrome and its severity with liver fibrosis: a cross-sectional study based on NHANES 2017–March 2020, 2021–2023
  Jiahui Yang, Xufeng Li, Fang Qi
  BMC Gastroenterology.2026;[Epub]     CrossRef
• AI Framework Integrated with InN Gas Sensing to Distinguish Sedentary Metabolic Fingerprints from Chronic Liver Disease
  Tsung Ming Chao, Rakesh Kumar Patnaik, Yu Chen Lin, Ming-Chih Ho, J. Andrew Yeh
  AI Sensors.2026; 2(2): 6.     CrossRef
• High Cardiometabolic Risk Burden Predicts Adverse Outcomes in Patients with MASLD-Related Hepatocellular Carcinoma
  Yeonhong Do, Young Hyeon Ahn, Young Chang, Jeong-Ju Yoo, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Hong Soo Kim, Keungmo Yang, Tom Ryu
  Gut and Liver.2026; 20(4): 655.     CrossRef
• Valorizing Agro‐Food Waste for Nutraceutical Development: Sustainable Approaches for Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Related Co‐Morbidities
  Laura Comi, Claudia Giglione, Fationa Tolaj Klinaku, Federico Pialorsi, Valentina Tollemeto, Maria Zurlo, Antonio Seneci, Paolo Magni
  Food Frontiers.2025; 6(2): 670.     CrossRef
• The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
  Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari,
  Journal of Clinical Medicine.2025; 14(2): 428.     CrossRef
• Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease
  Li-Hui Zhang, Su-Tong Liu, Qing Zhao, Xiao-Yan Liu, Tong Liu, Qiang Zhang, Ming-Hao Liu, Wen-Xia Zhao
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease
  Jun Arai, Akinori Okumura, Satoshi Kimoto, Kazumasa Sakamoto, Tomoya Kitada, Rena Kitano, Tadahisa Inoue, Sayaka Nishimura, Noriko Inden, Yukiko Muraki, Naoya Kato, Kiyoaki Ito
  Hepatology International.2025; 19(4): 836.     CrossRef
• Metabolic Sparks in the Liver: Metabolic and Epigenetic Reprogramming in Hepatic Stellate Cells Activation and Its Implications for Human Metabolic Diseases
  Yeon Jin Roh, Hyeonki Kim, Dong Wook Choi
  Diabetes & Metabolism Journal.2025; 49(3): 368.     CrossRef
• Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
  Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
  Diabetes & Metabolism Journal.2025; 49(3): 348.     CrossRef
• Trends and visualization analysis of research on MASLD-Related hepatocellular carcinoma: a bibliometric analysis
  Hongkun Yin, Xusheng Zhang, Qi Wang
  Discover Oncology.2025;[Epub]     CrossRef
• Elucidating the mechanistic interplay of AMPK and Nrf2 in MASLD: A focus on dietary phytochemical modulation of lipid and redox homeostasis
  Cindy H.J. Yu, H.P. Vasantha Rupasinghe
  Biochemical and Biophysical Research Communications.2025; 777: 152300.     CrossRef
• Notch signaling in metabolic diseases: A key regulator and potential target
  Zhaoqing Xi, Junxia Zhang, Mingwei Bao
  Biochemical and Biophysical Research Communications.2025; 781: 152492.     CrossRef
• Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
  Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero
  International Journal of Molecular Sciences.2025; 26(23): 11425.     CrossRef
• Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques
  Sergio Gil-Rojas, Miguel Suárez, Pablo Martínez-Blanco, Ana M. Torres, Natalia Martínez-García, Pilar Blasco, Miguel Torralba, Jorge Mateo
  Metabolites.2024; 14(6): 305.     CrossRef
• Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
  Na Young Lee, Myeung Gi Choi, Eui Jin Lee, Ja Hyun Koo
  Archives of Pharmacal Research.2024; 47(6): 558.     CrossRef
• New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?
  Marzia Tagliaferro, Mariapaola Marino, Valerio Basile, Krizia Pocino, Gian Ludovico Rapaccini, Gabriele Ciasca, Umberto Basile, Valeria Carnazzo
  Journal of Personalized Medicine.2024; 14(8): 798.     CrossRef
• AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response
  Feng Liu, Yameng Sun, Dean Tai, Yayun Ren, Elaine L. K. Chng, Aileen Wee, Pierre Bedossa, Rui Huang, Jian Wang, Lai Wei, Hong You, Huiying Rao
  Diagnostics.2024; 14(16): 1837.     CrossRef
• Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation
  Harrison T. Muturi, Hilda E. Ghadieh, Suman Asalla, Sumona G. Lester, Getachew D. Belew, Sobia Zaidi, Raziyeh Abdolahipour, Abhishek P. Shrestha, Agnes O. Portuphy, Hannah L. Stankus, Raghd Abu Helal, Stefaan Verhulst, Sergio Duarte, Ali Zarrinpar, Leo A.
  Molecular Metabolism.2024; 88: 102010.     CrossRef
• The impact of traditional Chinese medicine and dietary compounds on modulating gut microbiota in hepatic fibrosis: A review
  Xingting Xue, Hongbing Zhou, Jiaxing Gao, Xinghua Li, Jia Wang, Wanfu Bai, Yingchun Bai, Liya Fan, Hong Chang, Songli Shi
  Heliyon.2024; 10(19): e38339.     CrossRef
• Beneficial Effects of Tyrosol and Oleocanthal from Extra Virgin Olive Oil on Liver Health: Insights into Their Mechanisms of Action
  Daniela Gabbia
  Biology.2024; 13(10): 760.     CrossRef
• Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFβ Signaling in Hepatic Stellate Cells
  Kavita Prasad, Dipankar Bhattacharya, Shams Gamal Eldin Shams, Kimberly Izarraras, Tia Hart, Brent Mayfield, Maryjka B. Blaszczyk, Zhongren Zhou, Utpal B. Pajvani, Scott L. Friedman, Moshmi Bhattacharya
  Cells.2024; 13(19): 1651.     CrossRef
• Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders
  Michal Selc, Radka Macova, Andrea Babelova
  Drug Design, Development and Therapy.2024; Volume 18: 4629.     CrossRef